Agilisium Receives Frost & Sullivan’s 2026 Global Technology Innovation Leadership Recognition for Agentic AI in Life Sciences
San Antonio, TX - September 9, 2026 - Moving artificial intelligence from experimentation into meaningful, production-scale applications is becoming increasingly important as life sciences organizations manage complex data, stringent regulations, and growing pressure to accelerate decision-making. Agilisium is helping address this need through a domain-oriented approach to agentic AI, enabling pharmaceutical, biotechnology, and life sciences organizations to apply intelligent automation across research, clinical development, market access, commercial operations, and patient services. Frost & Sullivan recognizes Agilisium with the 2026 Global Technology Innovation Leadership Recognition in the Agentic AI for Life Sciences industry for its ability to translate emerging AI capabilities into scalable, production-ready solutions for highly regulated environments.
Frost & Sullivan evaluates companies through a rigorous benchmarking process across two core dimensions: strategy effectiveness and strategy execution. Agilisium distinguished itself through its proprietary Domain-Oriented Agentic AI framework, which combines purpose-built agents, enterprise data, workflow orchestration, and embedded governance to support secure and accountable AI adoption. “Agilisium’s agentic AI architecture includes human-in-the-loop controls, confidence thresholds, fallback routing, role-based access, audit trails, and source attribution. For regulated workflows, human sign-off is built into the process before downstream action,” said Surbhi Gupta, Industry Principal, HLS, Frost & Sullivan.
Founded in 2014, Agilisium has emerged as the world’s only Life Sciences Context-Centric AI Consulting & Services Company, with capabilities spanning Molecule to Market. With more than 1,050 employees, six global delivery centers, and more than 25 global life sciences customers. The company supports leading pharmaceutical, biotechnology, and life sciences organizations across North America, Europe, and other major markets. Its client base includes Fortune 500 and Global 2000 biopharma companies, while the company reports more than 190 live projects and an average customer satisfaction rating of 4.75 out of 5.
The company’s technology strategy is supported by a portfolio of production-grade platforms and accelerators, including its Agentic AI Global Value Dossier Content Generator, ClinQC, Site Risk Assessment and Inspection Readiness, Protocol Digitization, Smart ICF Generation, MLR Review Acceleration AI, Literature AI, Queriosity, OncoVerse AI, Launch Intelligence Platform, and Prior Authorization AI. Together, these solutions help organizations address complex workflows without treating AI as a standalone technology layer.
Agilisium further differentiates its approach through its Forward Deployment model, which combines Forward Deployment Experts, Forward Deployed Agents, and Forward Deployed Services. Supported by Alexandria AI, an AI-native Capability Orchestration and Readiness Engine, which enables enterprises to identify opportunities, develop and validate agentic solutions, and accelerate adoption. Agilisium reports that this approach can move from an identified opportunity to a working agent in approximately 60 days.
Responsible AI is embedded throughout the company’s approach, with capabilities including human-in-the-loop controls, model risk documentation, retrieval-augmented generation, drift monitoring, golden-set and regression testing, privacy controls, and client-managed data tenancies. Its Agentic Readiness Assessment also evaluates use cases based on business value, data readiness, process repeatability, regulatory risk, integration complexity, and adoption potential.
Agilisium’s approach has delivered measurable customer outcomes. The company reports up to 90% faster study setup, 60% to 70% faster amendment processing, 80% faster site risk assessments, and a 50% reduction in protocol deviations. Its Literature AI capabilities have reduced literature review effort by 70% to 80%, while its Global Value Dossier Content Generator has reduced value dossier development time by 60% in reference deployments.
Frost & Sullivan commends Agilisium for establishing a differentiated model for applying agentic AI within complex and regulated life sciences environments. By combining specialized domain expertise, scalable AI architecture, reusable accelerators, enterprise integration, and embedded governance, Agilisium is helping organizations move beyond AI experimentation toward measurable, production-scale transformation.
Each year, Frost & Sullivan presents the Technology Innovation Leadership Recognition to a company that demonstrates excellence in developing and implementing innovative technologies that deliver meaningful customer value and strengthen competitive positioning. The recognition highlights organizations whose technology strategies address evolving market needs while establishing a foundation for sustained growth and industry leadership.
About Agilisium
Agilisium is the world’s only Life Sciences Context-Centric AI Consulting & Services company, delivering transformation from Molecule to Market. By combining deep Life Sciences context with AI, data, analytics, cloud, and intelligent automation, Agilisium helps pharmaceutical, biotechnology, and medical technology organizations solve complex business challenges and achieve measurable outcomes.
Media Contact
Srivathsan Sridharan
www.agilisium.com
